Affymetrix Board Agrees to Discuss $1.85B Acquisition Bid With Origin Technologies | GenomeWeb

NEW YORK (GenomeWeb) – Affymetrix said today that its board now plans to engage in discussions with Origin Technologies regarding its most recent proposal to acquire Affy for $17.00 per share in an all-cash transaction.

However, Affy's board of directors said it continues to recommend that its stockholders vote in favor of the adoption of a previously approved merger with Thermo Fisher Scientific, in which Thermo Fisher would acquire Affy for $14 per share, or approximately $1.3 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.